<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9">
  <url>
    <loc>https://pepsreview.com/articles/semaglutide-resmetirom-mash-indirect-comparison-weight-loss</loc>
    <news:news>
      <news:publication>
        <news:name>PepsReview</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-07</news:publication_date>
      <news:title><![CDATA[Semaglutide Beats Resmetirom on MASH Resolution in First Indirect Comparison, but a Cardiovascular Signal Cuts the Other Way]]></news:title>
      <news:keywords>semaglutide, resmetirom, MASH, MASH treatment comparison, ESSENCE trial, MAESTRO-NASH, GLP-1 liver disease, MASH fibrosis</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://pepsreview.com/articles/fda-28-day-vial-rule-glp1-api-border-alert</loc>
    <news:news>
      <news:publication>
        <news:name>PepsReview</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-07</news:publication_date>
      <news:title><![CDATA[FDA Adds a 28-Day Vial Rule and a Border Alert to Its Compounded GLP-1 Guidance]]></news:title>
      <news:keywords>compounded GLP-1, FDA guidance, multi-dose vial, retatrutide, cagrilintide, import alert 66-80, peptide testing</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://pepsreview.com/articles/lilly-nad-good-life-compounded-tirzepatide-claims</loc>
    <news:news>
      <news:publication>
        <news:name>PepsReview</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-06</news:publication_date>
      <news:title><![CDATA[Lilly Forces Telehealth Rival to Drop 'Personalized' Compounded Tirzepatide Claims]]></news:title>
      <news:keywords>compounded tirzepatide, Eli Lilly, National Advertising Division, Good Life Meds, GLP-1 enforcement, peptide regulation, telehealth weight loss</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://pepsreview.com/articles/clinicians-push-back-six-unapproved-peptides-compounding-policy</loc>
    <news:news>
      <news:publication>
        <news:name>PepsReview</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-06</news:publication_date>
      <news:title><![CDATA[Clinicians Push Back as Washington Loosens Rules on Six Unapproved Peptides]]></news:title>
      <news:keywords>peptide compounding, BPC-157, TB-500, FDA enforcement discretion, unapproved peptides, peptide safety, compounded peptides, HHS peptide policy</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://pepsreview.com/articles/lilly-mevidalen-alzheimer-phase-2-pipeline-removal</loc>
    <news:news>
      <news:publication>
        <news:name>PepsReview</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-06</news:publication_date>
      <news:title><![CDATA[Lilly Drops Mevidalen After Phase 2 Alzheimer's Miss, Leaving D1 Data Undisclosed]]></news:title>
      <news:keywords>mevidalen, Eli Lilly Alzheimer's, dopamine D1 PAM, phase 2 Alzheimer's trial, peptide research, CNS drug development, neuroscience pipeline</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://pepsreview.com/articles/tirzepatide-high-dose-semaglutide-indirect-comparison-4-5-points</loc>
    <news:news>
      <news:publication>
        <news:name>PepsReview</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-06</news:publication_date>
      <news:title><![CDATA[Tirzepatide Beat High-Dose Semaglutide by 4.5 Points - With an Asterisk]]></news:title>
      <news:keywords>tirzepatide, semaglutide, Zepbound, Wegovy HD, indirect treatment comparison, SURMOUNT-5, GLP-1 obesity trials, peptide evidence</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://pepsreview.com/articles/novo-third-outlook-raise-wegovy-pill-rollout-q3-2026</loc>
    <news:news>
      <news:publication>
        <news:name>PepsReview</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-06</news:publication_date>
      <news:title><![CDATA[Novo Raises 2026 Outlook a Third Time as the Wegovy Pill Carries the Quarter]]></news:title>
      <news:keywords>Novo Nordisk, Wegovy pill, oral semaglutide, GLP-1 market, obesity drugs, Eli Lilly, peptide supply, GLP-1 pricing</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://pepsreview.com/articles/brazil-anvisa-clears-dr-reddys-generic-semaglutide</loc>
    <news:news>
      <news:publication>
        <news:name>PepsReview</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-05</news:publication_date>
      <news:title><![CDATA[Brazil Clears Dr Reddy's Generic Semaglutide After April Rejection]]></news:title>
      <news:keywords>generic semaglutide, ANVISA approval, Dr Reddy's Brazil, Ozempic generic, peptide regulation, GLP-1 supply chain, peptide testing</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://pepsreview.com/articles/new-zealand-needle-exchange-peptide-kits-2300-six-weeks</loc>
    <news:news>
      <news:publication>
        <news:name>PepsReview</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-05</news:publication_date>
      <news:title><![CDATA[New Zealand's Needle Exchange Now Hands Out Peptide Kits — and 40% of Its Clients Want Them]]></news:title>
      <news:keywords>peptide injecting kits, needle exchange New Zealand, unapproved peptides, Medsafe peptide warning, harm reduction, BPC-157, retatrutide, peptide regulation</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://pepsreview.com/articles/glp1-vs-metformin-prediabetes-256000-patient-study</loc>
    <news:news>
      <news:publication>
        <news:name>PepsReview</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-05</news:publication_date>
      <news:title><![CDATA[GLP-1 Drugs Beat Metformin on Diabetes Prevention in a 256,000-Patient Study — With Real Caveats]]></news:title>
      <news:keywords>GLP-1 prediabetes, metformin comparison, type 2 diabetes prevention, semaglutide, tirzepatide, AHA Scientific Sessions 2026, observational study</news:keywords>
    </news:news>
  </url>
  <url>
    <loc>https://pepsreview.com/articles/generic-semaglutide-india-exports-torrent-brazil</loc>
    <news:news>
      <news:publication>
        <news:name>PepsReview</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-05</news:publication_date>
      <news:title><![CDATA[Generic Semaglutide Is Leaving India — Torrent Targets Brazil Within Nine Months]]></news:title>
      <news:keywords>generic semaglutide, Torrent Pharmaceuticals, Brazil semaglutide patent, India generics, GLP-1 supply chain, Novo Nordisk patent expiry</news:keywords>
    </news:news>
  </url>
</urlset>